Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 2
2018 2
2019 5
2020 4
2021 1
2022 7
2023 8
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Cardiac Tumors: Review.
Karigyo CJT, Pessoa BMS, Nicacio SP, Terwilliger E, Costa P, Santos PRD, Ernani V, Seetharam M, Murakami AN, Batalini F. Karigyo CJT, et al. Among authors: batalini f. Braz J Cardiovasc Surg. 2024 Jul 22;39(6):e20230405. doi: 10.21470/1678-9741-2023-0405. Braz J Cardiovasc Surg. 2024. PMID: 39038269 Free PMC article. Review.
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.
Wang L, Wang D, Sonzogni O, Ke S, Wang Q, Thavamani A, Batalini F, Stopka SA, Regan MS, Vandal S, Tian S, Pinto J, Cyr AM, Bret-Mounet VC, Baquer G, Eikesdal HP, Yuan M, Asara JM, Heng YJ, Bai P, Agar NYR, Wulf GM. Wang L, et al. Among authors: batalini f. Cell Rep. 2022 Oct 11;41(2):111462. doi: 10.1016/j.celrep.2022.111462. Cell Rep. 2022. PMID: 36223740 Free PMC article.
An overview of artificial intelligence in oncology.
Farina E, Nabhen JJ, Dacoregio MI, Batalini F, Moraes FY. Farina E, et al. Among authors: batalini f. Future Sci OA. 2022 Feb 10;8(4):FSO787. doi: 10.2144/fsoa-2021-0074. eCollection 2022 Apr. Future Sci OA. 2022. PMID: 35369274 Free PMC article. Review.
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry.
Ke S, Dang F, Wang L, Chen JY, Naik MT, Li W, Thavamani A, Kim N, Naik NM, Sui H, Tang W, Qiu C, Koikawa K, Batalini F, Stern Gatof E, Isaza DA, Patel JM, Wang X, Clohessy JG, Heng YJ, Lahav G, Liu Y, Gray NS, Zhou XZ, Wei W, Wulf GM, Lu KP. Ke S, et al. Among authors: batalini f. Nat Commun. 2024 Apr 15;15(1):3220. doi: 10.1038/s41467-024-47427-w. Nat Commun. 2024. PMID: 38622115 Free PMC article.
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature.
Batalini F, Madison RW, Sokol ES, Jin DX, Chen KT, Decker B, Pavlick DC, Frampton GM, Wulf GM, Garber JE, Oxnard G, Schrock AB, Tung NM. Batalini F, et al. JCO Precis Oncol. 2023 Sep;7:e2300091. doi: 10.1200/PO.23.00091. JCO Precis Oncol. 2023. PMID: 37992259 Free PMC article.
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F. Menezes MCS, et al. Among authors: batalini f. Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332. Cancers (Basel). 2022. PMID: 36077867 Free PMC article. Review.
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, Shapiro GI, Adalsteinsson V, Winer EP, Konstantinopoulos PA, D'Andrea A, Swisher EM, Matulonis UA, Wulf GM, Mayer EL. Batalini F, et al. Clin Cancer Res. 2022 Apr 14;28(8):1493-1499. doi: 10.1158/1078-0432.CCR-21-3045. Clin Cancer Res. 2022. PMID: 35149538 Free PMC article. Clinical Trial.
38 results